Evidence map›Paper›PMID 21039416›Full record

ArticleBritish journal of pharmacology2011

Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.

M Cazorla, J M Arrang, J Prémont

Open access · greenAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Novel CAR-T cells targeting TRKB for the treatment of solid cancer.Apoptosis : an international journal on programmed cell death · 2024
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Fully human agonist antibodies to TrkB using autocrine cell-based selection from a combinatorial antibody library.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  10. Neuroprotective strategies for retinal disease.Progress in retinal and eye research · 2018
    Review
  11. Article
  12. Article
  13. Review
  14. Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

M CazorlaLaboratory of Neurobiology & Molecular Pharmacology, Centre de Psychiatrie et Neurosciences, UMR-894 INSERM/Université Paris Descartes, 2Ter rue d'Alésia, Paris, France. mc3195@columbia.edu
J M Arrang
J Prémont
Université Paris Cité · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeBy interacting with trkB receptors, brain-derived neurotrophic factor (BDNF) triggers various signalling pathways responsible for neurone survival, differentiation and modulation of synaptic transmission. Numerous reports have implicated BDNF and trkB in the pathogenesis of various central nervous system affections and in cancer, thus representing trkB as a promising therapeutic target. In this study, we used an antibody-based approach to search for trkB-selective functional reagents. EXPERIMENTAL APPROACH: Six commercially available polyclonal and monoclonal antibodies were tested on recombinant and native, human and rodent trkB receptors. Functional and pharmacological characterization was performed using a modified version of the KIRA-elisa method and radioligand binding studies. Western blot analyses and neurite outgrowth assays were carried out to determine the specificity and selectivity of antibody effects. The survival properties of one antibody were further assessed on cultured neurones in a serum-deprived paradigm. KEY

resultsThe functional trkB-selective antibodies showed distinct pharmacological profiles, ranging from partial agonists to antagonists, acting on trkB receptors through allosteric modulations. The same diversity of effects was observed on the mitogen-activated protein kinase signalling pathway downstream of trkB and on the subsequent neurite outgrowth. One antibody with partial agonist activity demonstrated cell survival properties by activating the Akt pathway. Finally, these antibodies were functionally validated as true trkB-selective ligands because they failed activating trkA or trkC, and contrary to BDNF, none of them bind to p75(NTR). CONCLUSIONS AND IMPLICATIONS: These trkB-selective antibodies represent a novel class of pharmacological tools to explore the pathophysiological roles of trkB and its potential therapeutic relevance for the treatment of various disorders.

Indexed as

Allosteric RegulationAnimalsAntibodiesAntibodies, MonoclonalAntibody SpecificityBrain-Derived Neurotrophic FactorCells, CulturedCell SurvivalCerebral CortexCHO CellsCricetinaeCricetulusEmbryo, MammalianHumansMiceNeuritesAntibodiesAntibodies, MonoclonalBrain-Derived Neurotrophic FactorReceptor, trkBRecombinant Fusion Proteins

Identifiers

PMID21039416
PMCPMC3042204
OpenAlexW1535069478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.